- call +1-201-465-4211
- email sales@mrinsights.biz
Researchers are working to develop new and improved therapies for people with Parkinson's disease (PD). There have been many drugs that have been approved to treat Parkinson disease.
Scope of the Report:
This report focuses on the Parkinsons disease Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Parkinsons disease Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Teva
Novartis AG
GSK
AbbVie
Merck
Boehringer Ingelheim
Impax Laboratories
Lundbeck
Sun Pharma
Wockhardt
UCB
Valeant Pharmaceuticals
Acadia
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Carbidopa/Levodopa
Dopamine Receptor Agonists
MAO-Inhibitors
Market Segment by Applications, can be divided into
Hospital
Online
Retail Pharmacies
There are 15 Chapters to deeply display the global Parkinsons disease Drug market.
Chapter 1, to describe Parkinsons disease Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Parkinsons disease Drug, with sales, revenue, and price of Parkinsons disease Drug, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Parkinsons disease Drug, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Parkinsons disease Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Parkinsons disease Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Parkinsons disease Drug Introduction
1.2 Market Analysis by Type
1.2.1 Carbidopa/Levodopa
1.2.2 Dopamine Receptor Agonists
1.2.3 MAO-Inhibitors
1.3 Market Analysis by Applications
1.3.1 Hospital
1.3.2 Online
1.3.3 Retail Pharmacies
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Teva
2.1.1 Business Overview
2.1.2 Parkinsons disease Drug Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Teva Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis AG
2.2.1 Business Overview
2.2.2 Parkinsons disease Drug Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis AG Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 GSK
2.3.1 Business Overview
2.3.2 Parkinsons disease Drug Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GSK Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 AbbVie
2.4.1 Business Overview
2.4.2 Parkinsons disease Drug Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 AbbVie Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Merck
2.5.1 Business Overview
2.5.2 Parkinsons disease Drug Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Merck Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Boehringer Ingelheim
2.6.1 Business Overview
2.6.2 Parkinsons disease Drug Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Boehringer Ingelheim Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Impax Laboratories
2.7.1 Business Overview
2.7.2 Parkinsons disease Drug Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Impax Laboratories Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Lundbeck
2.8.1 Business Overview
2.8.2 Parkinsons disease Drug Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Lundbeck Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Sun Pharma
2.9.1 Business Overview
2.9.2 Parkinsons disease Drug Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Sun Pharma Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Wockhardt
2.10.1 Business Overview
2.10.2 Parkinsons disease Drug Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Wockhardt Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 UCB
2.11.1 Business Overview
2.11.2 Parkinsons disease Drug Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 UCB Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Valeant Pharmaceuticals
2.12.1 Business Overview
2.12.2 Parkinsons disease Drug Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Valeant Pharmaceuticals Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Acadia
2.13.1 Business Overview
2.13.2 Parkinsons disease Drug Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Acadia Parkinsons disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Parkinsons disease Drug Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Parkinsons disease Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Parkinsons disease Drug Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Parkinsons disease Drug Manufacturer Market Share in 2017
3.3.2 Top 6 Parkinsons disease Drug Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Parkinsons disease Drug Market Analysis by Regions
4.1 Global Parkinsons disease Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Parkinsons disease Drug Sales and Market Share by Regions (2013-2018)
4.1.2 Global Parkinsons disease Drug Revenue and Market Share by Regions (2013-2018)
4.2 North America Parkinsons disease Drug Sales and Growth Rate (2013-2018)
4.3 Europe Parkinsons disease Drug Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Parkinsons disease Drug Sales and Growth Rate (2013-2018)
4.5 South America Parkinsons disease Drug Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Parkinsons disease Drug Sales and Growth Rate (2013-2018)
5 North America Parkinsons disease Drug by Countries
5.1 North America Parkinsons disease Drug Sales, Revenue and Market Share by Countries
5.1.1 North America Parkinsons disease Drug Sales and Market Share by Countries (2013-2018)
5.1.2 North America Parkinsons disease Drug Revenue and Market Share by Countries (2013-2018)
5.2 United States Parkinsons disease Drug Sales and Growth Rate (2013-2018)
5.3 Canada Parkinsons disease Drug Sales and Growth Rate (2013-2018)
5.4 Mexico Parkinsons disease Drug Sales and Growth Rate (2013-2018)
6 Europe Parkinsons disease Drug by Countries
6.1 Europe Parkinsons disease Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe Parkinsons disease Drug Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Parkinsons disease Drug Revenue and Market Share by Countries (2013-2018)
6.2 Germany Parkinsons disease Drug Sales and Growth Rate (2013-2018)
6.3 UK Parkinsons disease Drug Sales and Growth Rate (2013-2018)
6.4 France Parkinsons disease Drug Sales and Growth Rate (2013-2018)
6.5 Russia Parkinsons disease Drug Sales and Growth Rate (2013-2018)
6.6 Italy Parkinsons disease Drug Sales and Growth Rate (2013-2018)
7 Asia-Pacific Parkinsons disease Drug by Countries
7.1 Asia-Pacific Parkinsons disease Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Parkinsons disease Drug Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Parkinsons disease Drug Revenue and Market Share by Countries (2013-2018)
7.2 China Parkinsons disease Drug Sales and Growth Rate (2013-2018)
7.3 Japan Parkinsons disease Drug Sales and Growth Rate (2013-2018)
7.4 Korea Parkinsons disease Drug Sales and Growth Rate (2013-2018)
7.5 India Parkinsons disease Drug Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Parkinsons disease Drug Sales and Growth Rate (2013-2018)
8 South America Parkinsons disease Drug by Countries
8.1 South America Parkinsons disease Drug Sales, Revenue and Market Share by Countries
8.1.1 South America Parkinsons disease Drug Sales and Market Share by Countries (2013-2018)
8.1.2 South America Parkinsons disease Drug Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Parkinsons disease Drug Sales and Growth Rate (2013-2018)
8.3 Argentina Parkinsons disease Drug Sales and Growth Rate (2013-2018)
8.4 Colombia Parkinsons disease Drug Sales and Growth Rate (2013-2018)
9 Middle East and Africa Parkinsons disease Drug by Countries
9.1 Middle East and Africa Parkinsons disease Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Parkinsons disease Drug Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Parkinsons disease Drug Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Parkinsons disease Drug Sales and Growth Rate (2013-2018)
9.3 UAE Parkinsons disease Drug Sales and Growth Rate (2013-2018)
9.4 Egypt Parkinsons disease Drug Sales and Growth Rate (2013-2018)
9.5 Nigeria Parkinsons disease Drug Sales and Growth Rate (2013-2018)
9.6 South Africa Parkinsons disease Drug Sales and Growth Rate (2013-2018)
10 Global Parkinsons disease Drug Market Segment by Type
10.1 Global Parkinsons disease Drug Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Parkinsons disease Drug Sales and Market Share by Type (2013-2018)
10.1.2 Global Parkinsons disease Drug Revenue and Market Share by Type (2013-2018)
10.2 Carbidopa/Levodopa Sales Growth and Price
10.2.1 Global Carbidopa/Levodopa Sales Growth (2013-2018)
10.2.2 Global Carbidopa/Levodopa Price (2013-2018)
10.3 Dopamine Receptor Agonists Sales Growth and Price
10.3.1 Global Dopamine Receptor Agonists Sales Growth (2013-2018)
10.3.2 Global Dopamine Receptor Agonists Price (2013-2018)
10.4 MAO-Inhibitors Sales Growth and Price
10.4.1 Global MAO-Inhibitors Sales Growth (2013-2018)
10.4.2 Global MAO-Inhibitors Price (2013-2018)
11 Global Parkinsons disease Drug Market Segment by Application
11.1 Global Parkinsons disease Drug Sales Market Share by Application (2013-2018)
11.2 Hospital Sales Growth (2013-2018)
11.3 Online Sales Growth (2013-2018)
11.4 Retail Pharmacies Sales Growth (2013-2018)
12 Parkinsons disease Drug Market Forecast (2018-2023)
12.1 Global Parkinsons disease Drug Sales, Revenue and Growth Rate (2018-2023)
12.2 Parkinsons disease Drug Market Forecast by Regions (2018-2023)
12.2.1 North America Parkinsons disease Drug Market Forecast (2018-2023)
12.2.2 Europe Parkinsons disease Drug Market Forecast (2018-2023)
12.2.3 Asia-Pacific Parkinsons disease Drug Market Forecast (2018-2023)
12.2.4 South America Parkinsons disease Drug Market Forecast (2018-2023)
12.2.5 Middle East and Africa Parkinsons disease Drug Market Forecast (2018-2023)
12.3 Parkinsons disease Drug Market Forecast by Type (2018-2023)
12.3.1 Global Parkinsons disease Drug Sales Forecast by Type (2018-2023)
12.3.2 Global Parkinsons disease Drug Market Share Forecast by Type (2018-2023)
12.4 Parkinsons disease Drug Market Forecast by Application (2018-2023)
12.4.1 Global Parkinsons disease Drug Sales Forecast by Application (2018-2023)
12.4.2 Global Parkinsons disease Drug Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Parkinsons disease Drug Picture
Table Product Specifications of Parkinsons disease Drug
Figure Global Sales Market Share of Parkinsons disease Drug by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
